We use cookies to see how investors use El Fondo and make its tools, data and markets better for you. You can accept or reject; essential cookies always stay on. Privacy Policy
Trades about 45% above its sector, the market expects faster growth.
Sakar Healthcare Limited, founded in 2004 and based in Ahmedabad, India, is a pharmaceutical company actively involved in the full spectrum of drug development, from research and manufacturing to marketing its products. The company's diverse product line includes liquid oral medications, cephalosporin-based drugs (available as tablets, capsules, and dry powder syrups), various injectable forms such as dry powder injections, and liquid injectable solutions (supplied in ampoules, vials, and lyophilized preparations), alongside oral solid dosages. Their comprehensive portfolio addresses approximately 22 distinct therapeutic categories, encompassing treatments for conditions like acidity, malaria, blood clotting, constipation, respiratory issues, pain, infections, depression, allergies, and nutritional deficiencies, among others. Sakar Healthcare also has a significant global reach, distributing its products to roughly 38 countries across regions including Southeast Asia, other parts of Asia, both English and French-speaking African nations, the Middle East and North Africa, and the United States.
Loading the full price history…
Run your own numbersPast performance is not a forecast.
Save SAKAR.NS and get told when something moves.
Get updates
A clear, direct weekly summary.
Learn the fundamentals behind this asset.
A stock is a fraction of ownership in a real company. Buy one share and you own a piece (usually a tiny piece) of every desk, factory, contract and brand the company runs. The price moves because the market keeps revising what that whole pie is worth.
The price-to-earnings ratio is how much investors are paying for one dollar of a company's profit. A multiple, never an absolute. Always compared to something: a sector, a region, the company's own past.
Dividend yield is the annual income a stock or ETF pays out, expressed as a percentage of what you paid for it. It is the visible part of total return: the cash that lands in your account every quarter, and the lever most retail investors actually feel.
Market cap is shares times price. A simple formula that produces wildly unequal numbers: a single US tech name can be worth more than every company on a LATAM exchange combined.
